DOTMTAAT

DOTAMTATE is a somatostatin analogue. DOTAMTATE marked 212Pb is promising for research of somatostatin receptor positive neuroendocrine tumors[1].

2415661-92-4

12352209

Drug Derivative

Others

Cancer

99.55

DMSO : 50 mg/mL (ultrasonic)

O=C([C@@H](NC([C@H](CSSC[C@H](NC([C@](NC([C@@H](NC1=O)CCCCN)=O)([H])[C@H](O)C)=O)C(N[C@H](C(O)=O)[C@H](O)C)=O)NC([C@H](NC(CN2CCN(CCN(CCN(CC2)CC(N)=O)CC(N)=O)CC(N)=O)=O)CC3=CC=CC=C3)=O)=O)CC4=CC=C(C=C4)O)N[C@@H]1CC5=CNC6=CC=CC=C56

C65H93N17O16S2

1432.67

[1]Stallons et al. Preclinical Investigation of 212Pb-DOTAMTATE for Peptide Receptor Radionuclide Therapy in a Neuroendocrine Tumor Model. Mol Cancer Ther. 2019 May;18 (5) :1012-1021.

Blue Ice

-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)

http://file.medchemexpress.com/batch_PDF/HY-P10920/DOTAMTATE-SDS-MedChemExpress.pdf

Peptides

No Development Reported